Odapipam - Revision history

Prab: CSV import

2025-02-20T01:42:39Z

CSV import

← Older revision		Revision as of 01:42, 20 February 2025
Line 34:		Line 34:
	[[Category:Research chemicals]]		[[Category:Research chemicals]]
	[[Category:Experimental drugs]]		[[Category:Experimental drugs]]
			<gallery>
			File:Odapipam.svg\|Odapipam
			</gallery>

Prab: /* Also see */

2025-01-13T20:30:06Z

Also see

← Older revision		Revision as of 20:30, 13 January 2025
Line 29:		Line 29:

	{{Receptor antagonists}}		{{Receptor antagonists}}
	{{~~Dopamine~~}}		{{Dopamine_receptor_modulators}}
	{{nt}}		{{nt}}
	[[Category:Dopamine antagonists]]		[[Category:Dopamine antagonists]]
	[[Category:Research chemicals]]		[[Category:Research chemicals]]
	[[Category:Experimental drugs]]		[[Category:Experimental drugs]]

Prab at 20:29, 13 January 2025

2025-01-13T20:29:14Z

@@ Line 1: / Line 1: @@
 {{Short description|A detailed overview of the pharmacological agent Odapipam}}
 '''Odapipam''' is a pharmacological compound that acts as a selective [[dopamine receptor]] D1 antagonist. It is primarily used in research settings to study the role of D1 receptors in various physiological and pathological processes.
@@ Line 49: / Line 30: @@
 {{Receptor antagonists}}
 {{Dopamine}}
+{{nt}}
 [[Category:Dopamine antagonists]]
 [[Category:Research chemicals]]
 [[Category:Experimental drugs]]

Prab: CSV import

2024-12-10T19:42:29Z

CSV import

New page

{{Short description|A detailed overview of the pharmacological agent Odapipam}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = 7,8-dihydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
| image = Odapipam_structure.png
| width = 200
| CAS_number = 123456-78-9
| PubChem = 123456
| ChemSpiderID = 123456
| UNII = 123456789A
| KEGG = D12345
| ChEMBL = 123456
| C=16
| H=17
| N=1
| O=2
| molecular_weight = 255.31 g/mol
}}

'''Odapipam''' is a pharmacological compound that acts as a selective [[dopamine receptor]] D1 antagonist. It is primarily used in research settings to study the role of D1 receptors in various physiological and pathological processes.

==Pharmacology==
Odapipam is known for its high affinity and selectivity for the D1 subtype of dopamine receptors. These receptors are predominantly found in the [[central nervous system]], particularly in areas such as the [[striatum]], [[cerebral cortex]], and [[hippocampus]]. By blocking these receptors, Odapipam can modulate dopaminergic signaling, which is crucial for understanding the role of dopamine in [[neurotransmission]], [[motor control]], and [[cognitive function]].

===Mechanism of Action===
Odapipam binds to the D1 dopamine receptors, preventing the natural ligand, dopamine, from activating these receptors. This antagonistic action results in the inhibition of the downstream signaling pathways that are typically activated by dopamine, such as the [[adenylate cyclase]] pathway, which leads to a decrease in the production of [[cyclic AMP]] (cAMP).

===Pharmacokinetics===
The pharmacokinetic profile of Odapipam includes its absorption, distribution, metabolism, and excretion. It is typically administered via the oral route in experimental settings. The compound is metabolized in the liver and excreted primarily through the kidneys. The half-life of Odapipam can vary depending on the species and the specific experimental conditions.

==Research Applications==
Odapipam is used extensively in preclinical research to explore the role of D1 receptors in various conditions, including:

* '''[[Parkinson's disease]]''': By blocking D1 receptors, researchers can study the compensatory mechanisms that occur in the dopaminergic system in response to receptor antagonism.
* '''[[Schizophrenia]]''': Investigating the effects of D1 receptor antagonism on cognitive and behavioral symptoms associated with schizophrenia.
* '''[[Addiction]]''': Understanding the role of D1 receptors in the reward pathways and their contribution to addictive behaviors.

==Safety and Toxicology==
While Odapipam is primarily used in research, its safety profile is an important consideration. In animal studies, high doses of Odapipam have been associated with adverse effects such as motor impairment and changes in behavior. However, these effects are dose-dependent and reversible upon discontinuation of the compound.

==Also see==
* [[Dopamine receptor]]
* [[D1 receptor]]
* [[Dopaminergic pathways]]
* [[Neurotransmitter]]
* [[Pharmacology]]

{{Receptor antagonists}}
{{Dopamine}}

[[Category:Dopamine antagonists]]
[[Category:Research chemicals]]
[[Category:Experimental drugs]]